New York State Teachers Retirement System Sells 600 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

New York State Teachers Retirement System lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,254 shares of the specialty pharmaceutical company’s stock after selling 600 shares during the period. New York State Teachers Retirement System’s holdings in Supernus Pharmaceuticals were worth $2,721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of SUPN. GAMMA Investing LLC grew its stake in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 398 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $43,000. Meeder Asset Management Inc. purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $47,000. Innealta Capital LLC bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth about $51,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares in the last quarter.

Supernus Pharmaceuticals Trading Down 3.6 %

Shares of NASDAQ:SUPN opened at $36.40 on Friday. The company has a market cap of $2.01 billion, a price-to-earnings ratio of 34.02 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a 12 month low of $23.47 and a 12 month high of $39.37. The company has a 50-day moving average price of $33.11 and a 200 day moving average price of $30.63.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.94% and a net margin of 9.16%. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the previous year, the business earned ($0.29) EPS. The company’s quarterly revenue was up 14.2% on a year-over-year basis. As a group, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on SUPN. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.